Breaking News on Global Pharmaceutical Technology & Manufacturing

Hot Topics > Lifecycle management

Lifecycle management

Lifecycle management

As R&D productivity declines and the age of blockbuster medicines reaches an end, the pharmaceutical industry is looking at ways to extend the profitable life of its products up to and beyond patent expiry.

West’s operating income drops in Q2

05-Aug-2009 - West Pharmaceutical Services’ operating income fell by 33 per cent in Q2 but the company reported that demand for some of its drug delivery technology is strong.

Positive Phase II for intranasal antiemetic

04-Aug-2009 - Shin Nippon Biomedical Laboratories (SNBL) has posted a positive first report on the Phase II trial of its intranasal antiemetic, which it claims is a more convenient treatment for cancer...

BioMarin: good news on Kuvan patents; bad news as costs hit Q2 profits

03-Aug-2009 - New US patents for the PKU drug Kuvan will “significantly strengthen” BioMarin’s position according to CEO Jean-Jacques Bienaime.

Medingo’s insulin patch approved; shares rocket

30-Jul-2009 - Medingo’s insulin dispensing patch has been approved by the US Food and Drug Administration (FDA), sending shares in its parent company soaring to a 12 month high.

News in brief

Wyeth shareholders OK Pfizer takeover

21-Jul-2009 -  Wyeth’s shareholders gave Pfizer’s $68bn (€48bn) takeover a ringing endorsement late yesterday, with 98 per cent voting in favour of the deal.

Pfizer may bid for Turkey’s Abdi Ibrahim

20-Jul-2009 -  Rumours suggest that US drug giant Pfizer is considering a bid for Turkish generics group Abdi Ibrahim as part of its strategy of expanding in emerging markets.

Pfizer plans Irish process lab, shelves SF unit and sells skin drugs to Graceway

07-Jul-2009 -  Pfizer will invest €11m ($15.3m) in a new kilo technology R&D laboratory at its API manufacturing facility in Ringaskiddy, Ireland.

News in brief

GSK buys 13 B-MS generics for North African market

06-Jul-2009 -  UK drug major GSK has paid Bristol-Myers Squibb’s (BSM) $23.2m (€16.6m) for 13 generic products that it sells in North Africa and the Middle East.

Mylan partners to create FOBs

30-Jun-2009 -  Mylan has followed Teva’s lead by partnering to develop follow-on biologics (FOB), with the Indian generic maker regarding Biocon as the “ideal partner” to help it enter the market. ...

Bio drugs to dominate top ten list by 2014

18-Jun-2009 - Seven of the top ten drugs will be biopharmaceuticals by 2014 according to sector analysts Evaluate Pharma.

Mega deals not ‘mega’ for Big Pharma R&D long term, says F&S

17-Jun-2009 - As rumours of a failed Sanofi Aventis’ bid for a US rival circulate, F&S’ analysis of M&As is well timed, even if its conclusions will be difficult reading for a...

FTC calls for biogenerics path and end of “pay for delay” deals

11-Jun-2009 -  The US Federal Trade Commission (FTC) believes that an effective FOB approval pathway and laws preventing “pay-for-delay” deals are the only ways of reducing the cost of biologic drugs.

FDA revises ICH Q8 guidance

10-Jun-2009 - The FDA has revised its guidance on ICH Q8, adding an annex that clarifies the original document and adds the principles of quality by design (QbD).

UK trade office may check GSK and Pfizer HIV joint-venture

28-May-2009 -  GSK and Pfizer’s HIV joint venture (JV) may be subject to an investigation by UK competition watchdog the Office of Fair Trading (OFT), according to various media reports.

BIO 2009: snapshot of an evolving biotech industry

22-May-2009 - in-Pharmatechnologist's Nick Taylor looks back on BIO 2009, an event at which uncertainty about the development of the biotechnology industry’s future shape dominated proceedings.

Healthcare reform could suffocate innovation; BIO 2009

22-May-2009 - Karl Rove and Senator Tom Daschle were among the political figures at BIO 2009 discussing how the US healthcare system should be reformed, which some believe could have grave consequences...

Biosimilar bill could be "stake in the heart"

19-May-2009 - In a session chaired by at BIO 2009 John Lechleiter, CEO at Eli Lilly, speakers discussed patent reform, biosimilar bills and why certain options on the table could be a...

Mutiple parameters are key to powder analysis, says Freeman

18-May-2009 -  Freeman Technologies, which showcased its FT4 Rheometer at Achema in Frankfurt, Germany, last week, says pharmaceutical powders are complex systems that require analysis of multiple parameters. 

Hospira calls time on US biogenerics delays

06-May-2009 -  Drug delivery specialist Hospira has set up a “biologics clock” that counts the amount spent on cell culture-derived medications in the US in a bid to highlight the potential savings...

Sanofi seeks collaborators for €200m biotech plant

05-May-2009 -  French drug major Sanofi Aventis has unveiled plans for a €200m ($268m) biotechnology investment at its manufacturing facility in Vitry-sur-Seine near Paris, under its collaborative Biolaunch project. 

Pfizer eyes FOBs and small to midsized deals

30-Apr-2009 -  Pfizer is monitoring opportunities in follow-on biologics and continuing to look for small to mid-sized deals as it plans for life without Lipitor, global revenues of which fell by 13...

Lilly & Amylin team up to create diabetes pen

30-Apr-2009 -  Eli Lilly and Amylin Pharmaceuticals are jointly developing an exenatide once weekly pen device, which should provide a more convenient way for diabetics to treat themselves.

Sanofi pulls plug on four Ph III drugs

29-Apr-2009 -  Sanofi-Aventis has halted development of four Phase III drugs in a “rigorous” pre-patent loss pipeline review that has also seen it drop four Phase II candidates and six Phase I...

Nanoparticles used to create topical Viagra rival

29-Apr-2009 -  Erectile dysfunction could be treated by a nanoparticle formulation applied directly to the penis, according to research, reducing the side effects that can occur when taking drugs like Viagra.

Hovione shows off Irish API plant

23-Apr-2009 -  API maker Hovione’s manufacturing facility in Cork, Ireland was unveiled at an opening ceremony yesterday just two weeks after the previous owner, global drug giant Pfizer, formally handed over the...

Key Industry Events


Access all events listing

Our events, Events from partners...